Cancer immunotherapy

Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy

Thursday, July 9, 2020 - 1:00pm

FT819 is the first-ever CAR T-cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line, and is engineered with several first-of-kind features designed to improve the safety and efficacy of CAR T-cell therapy.

Key Points: 
  • FT819 is the first-ever CAR T-cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line, and is engineered with several first-of-kind features designed to improve the safety and efficacy of CAR T-cell therapy.
  • The clearance of our IND application for FT819 is a ground-breaking milestone in the field of cell-based cancer immunotherapy.
  • FT819 was designed to specifically address several limitations associated with the current generation of patient- and donor-derived CAR T-cell therapies.
  • Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.

Therapeutic Solutions International Submits Publication on StemVacs™ Preclinical Data Supporting COVID-19 Indication

Tuesday, July 7, 2020 - 2:00pm

OCEANSIDE, Calif., July 7, 2020 /PRNewswire/ --Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced submission of a publication providing preclinical data which supports repositioning of its Cancer Immunotherapy StemVacs as a candidate for treatment of COVID-19.

Key Points: 
  • OCEANSIDE, Calif., July 7, 2020 /PRNewswire/ --Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced submission of a publication providing preclinical data which supports repositioning of its Cancer Immunotherapy StemVacs as a candidate for treatment of COVID-19.
  • The current data suggests that StemVacs can activate natural killer cells while at the same time suppressing lung inflammation.
  • We believe that the data we are submitting for publication strongly supports efficacy" said Timothy Dixon, President and CEO of the Company.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

Aichi Cancer Center and NEC Launch Joint Research on Fundamental Study Aimed at Advanced Cancer Immunotherapy

Monday, July 6, 2020 - 7:11am

The Division of Translational Oncoimmunology at the Aichi Cancer Center has been conducting translational research using patient samples in collaboration with the departments of Thoracic Surgery and Thoracic Oncology at the Aichi Cancer Center Hospital.

Key Points: 
  • The Division of Translational Oncoimmunology at the Aichi Cancer Center has been conducting translational research using patient samples in collaboration with the departments of Thoracic Surgery and Thoracic Oncology at the Aichi Cancer Center Hospital.
  • Aichi Cancer Center and NEC will identify neoantigens recognized by T cells by using both the neoantigen prediction system and the immunological experimental approach.
  • Aichi Cancer Center will aim to carry out clinical trials of cancer immunotherapy.
  • The clinical trials of cancer immunotherapy will be conducted at Aichi Cancer Center Hospital, and additional research will be conducted at Aichi Cancer Center Research Institute.

CytoDyn Releases Mechanism of Action Animation for Leronlimab in Immuno-Oncology

Thursday, July 2, 2020 - 11:00am

CytoDyn is currently exploring the efficacy of leronlimab for several immuno-oncology indications, including metastatic triple-negative breast cancer, a mechanism of action basket trial for 22 solid tumors, and a Phase 2 combination therapy for metastatic colorectal cancer.

Key Points: 
  • CytoDyn is currently exploring the efficacy of leronlimab for several immuno-oncology indications, including metastatic triple-negative breast cancer, a mechanism of action basket trial for 22 solid tumors, and a Phase 2 combination therapy for metastatic colorectal cancer.
  • The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases.
  • CytoDyn has Fast Track designation for leronlimab and a rolling review for its BLA, as previously assigned by the FDA.
  • CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.

BioInvent Extends Research Collaboration and License Agreement With Pfizer Inc.

Wednesday, July 1, 2020 - 9:28am

LUND, Sweden, July 1, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that it has further extended the research term under its cancer immunotherapy research collaboration and license agreement with Pfizer Inc. ("Pfizer") until the end of 2020.

Key Points: 
  • LUND, Sweden, July 1, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that it has further extended the research term under its cancer immunotherapy research collaboration and license agreement with Pfizer Inc. ("Pfizer") until the end of 2020.
  • The purpose of the research extension is to permit the companies to further identify and characterize new targets and antibodies binding to these targets.
  • In 2019 Pfizer selected the first and second target under the agreement, which triggered two payments from Pfizer to BioInvent of $300,000.
  • antibody library.This extension provides Pfizer additional time to select optimal antibodies to their targets, as well as to explore more targets and corresponding antibodies.

BioInvent Extends Research Collaboration and License Agreement With Pfizer Inc.

Wednesday, July 1, 2020 - 9:23am

LUND, Sweden, July 1, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that it has further extended the research term under its cancer immunotherapy research collaboration and license agreement with Pfizer Inc. ("Pfizer") until the end of 2020.

Key Points: 
  • LUND, Sweden, July 1, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that it has further extended the research term under its cancer immunotherapy research collaboration and license agreement with Pfizer Inc. ("Pfizer") until the end of 2020.
  • The purpose of the research extension is to permit the companies to further identify and characterize new targets and antibodies binding to these targets.
  • In 2019 Pfizer selected the first and second target under the agreement, which triggered two payments from Pfizer to BioInvent of $300,000.
  • antibody library.This extension provides Pfizer additional time to select optimal antibodies to their targets, as well as to explore more targets and corresponding antibodies.

FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Tuesday, June 30, 2020 - 11:45pm

For patients that do not progress on platinum-containing chemotherapy, BAVENCIO is administered as a first-line maintenance treatment until disease progression or unacceptable toxicity.

Key Points: 
  • For patients that do not progress on platinum-containing chemotherapy, BAVENCIO is administered as a first-line maintenance treatment until disease progression or unacceptable toxicity.
  • BAVENCIO (avelumab) is indicated in the US for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.
  • In the US, the FDA granted accelerated approval for BAVENCIO for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).
  • A fatal adverse reaction (sepsis) occurred in one (0.3%) patient with locally advanced or metastatic urothelial carcinoma (UC) receiving BAVENCIOplus best supportive care (BSC) as first-line maintenance treatment.

Therapeutic Solutions International Universal Donor Immunotherapy StemVacs™ Activates Antiviral Immune Cells While Protecting Lungs From "Cytokine Storm"

Tuesday, June 30, 2020 - 3:35pm

StemVacs is a cell-based drug comprised of dendritic cells activated in a proprietary manner which when administered stimulates a type of immune system cell termed "natural killer" or NK cells.

Key Points: 
  • StemVacs is a cell-based drug comprised of dendritic cells activated in a proprietary manner which when administered stimulates a type of immune system cell termed "natural killer" or NK cells.
  • Numerous studies have shown that NK cells are involved in protecting the body from cancer and from viruses.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.
  • Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system.

CEL-SCI Corporation Receives $10 Million Through Warrant Exercises

Tuesday, June 30, 2020 - 1:30pm

CEL-SCI Corporation (NYSE American: CVM) announced today that, during the quarter ending June 30, 2020 it has received approximately $10 million from the exercise of warrants.

Key Points: 
  • CEL-SCI Corporation (NYSE American: CVM) announced today that, during the quarter ending June 30, 2020 it has received approximately $10 million from the exercise of warrants.
  • These funds will allow the Company to complete the expansion of its Multikine* (Leukocyte Interleukin, Inj.)
  • cancer immunotherapy manufacturing facility near Baltimore, MD in anticipation of BLA submission and subsequent marketing approval.
  • CEL-SCI believes that boosting a patients immune system while it is still intact should provide the greatest possible impact on survival.

FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer

Monday, June 29, 2020 - 8:33pm

This marks the first immunotherapy approved for thispatient population as a first-line treatment and which is administered to patients without also giving chemotherapy.

Key Points: 
  • This marks the first immunotherapy approved for thispatient population as a first-line treatment and which is administered to patients without also giving chemotherapy.
  • The frequency of MSI-H varies across tumor types and stages, and approximately 5% of patients with metastatic colorectal cancer have MSI-H or dMMR tumors.
  • "Metastatic colorectal cancer is a serious and life-threatening disease with a poor prognosis.
  • By blocking this pathway, Keytruda may help the body's immune system fight the cancer cells and provide a benefit in patients with MSI-H or dMMR metastatic colorectal cancer.